Cleared Traditional

K860873 - VENTURI MASK/ADULT & PAEDIATRIC (FDA 510(k) Clearance)

Class I Anesthesiology device.

K860873 · Dhd Medical Products Div. Diemolding Corp. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1986
Decision
23d
Days
Class 1
Risk

K860873 is an FDA 510(k) clearance for the VENTURI MASK/ADULT & PAEDIATRIC. Classified as Mask, Oxygen, Low Concentration, Venturi (product code BYF), Class I - General Controls.

Submitted by Dhd Medical Products Div. Diemolding Corp. (Canastota, US). The FDA issued a Cleared decision on March 20, 1986 after a review of 23 days - a notably fast clearance cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.5600 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Dhd Medical Products Div. Diemolding Corp. devices

Submission Details

510(k) Number K860873 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 25, 1986
Decision Date March 20, 1986
Days to Decision 23 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
116d faster than avg
Panel avg: 139d · This submission: 23d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code BYF Mask, Oxygen, Low Concentration, Venturi
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 868.5600
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.